| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 University Department of Medicine, University of Western Australia and the Western Australia Institute for Medical Research, Royal Perth Hospital, Perth, Western Australia WA 6847, Australia.
aAddress correspondence to this author at: The Department of Medicine, The University of Western Australia and the Western Australian Institute for Medical Research, Perth, Western Australia WA 6847, Australia. Fax 61-8-9224-0246; e-mail gfwatts{at}cyllene.uwa.edu.au.
Background: Chronic low-grade inflammation may contribute to the increased risk of atherosclerosis in visceral obesity. Statin and fish oil have been reported to have antiinflammatory effects. We studied whether dyslipidemic, obese individuals have increased plasma high-sensitivity C-reactive protein (hs-CRP) concentrations and whether treatment with atorvastatin and fish oil lowered plasma hs-CRP concentrations.
Methods: We compared plasma hs-CRP, interleukin-6 (IL-6), and tumor necrosis factor-
(TNF-) concentrations in 48 obese individuals with the concentrations in 10 lean normolipidemic men. The obese individuals were then randomized to treatment with atorvastatin (40 mg/day), fish oil (4 g/day), atorvastatin plus fish oil, or matching placebo for 6 weeks.
Results: Compared with controls, obese individuals had increased hs-CRP [geometric mean, 2.19 mg/L (95% confidence interval, 2.15–3.15 mg/L) vs 0.49 mg/L (0.30– 0.93 mg/L); P <0.001] and IL-6 [351 pg/L (318–449 pg/L) vs 251 pg/L (211–305 pg/L); P <0.01]. Atorvastatin treatment had a significant main effect of decreasing plasma hs-CRP (-0.87 mg/L; 95% confidence interval, -0.10 to -1.60 mg/L; P <0.01) and IL-6 (-70 pg/L; 10 to -140 pg/L; P <0.01), but this was not seen with fish oil. The reductions in hs-CRP with atorvastatin were not significantly correlated to changes in plasma lipids, IL-6, insulin resistance, or cholesterogenesis. Plasma TNF- concentrations in obese individuals, however, were neither statistically different from concentrations in the lean controls nor altered with atorvastatin or fish oil treatment.
Conclusions: This study shows that visceral obesity is associated with increased plasma hs-CRP and IL-6 and, hence, a low-grade chronic inflammatory state and that treatment with atorvastatin or atorvastatin with fish oil, but not fish oil alone, reverses this abnormality.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S. Kinlay Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Ignarro, M. L. Balestrieri, and C. Napoli Nutrition, physical activity, and cardiovascular disease: An update Cardiovasc Res, January 15, 2007; 73(2): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. van Doorn, S. M E. Santo, P. Meijer, I. M Kamerling, R. C Schoemaker, V. Dirsch, A. Vollmar, T. Haffner, R. Gebhardt, A. F Cohen, et al. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1324 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Giugliano, A. Ceriello, and K. Esposito The Effects of Diet on Inflammation: Emphasis on the Metabolic Syndrome J. Am. Coll. Cardiol., August 15, 2006; 48(4): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Basu, S. Devaraj, and I. Jialal Dietary Factors That Promote or Retard Inflammation Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 995 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease Clin. Chem., May 1, 2006; 52(5): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S von Haehling and S D Anker Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart, January 1, 2005; 91(1): 1 - 2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T Erkkila, A. H Lichtenstein, D. Mozaffarian, and D. M Herrington Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease Am. J. Clinical Nutrition, September 1, 2004; 80(3): 626 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes, P. A Howard, and P. M Moriarty Role of C-Reactive Protein in Cardiovascular Disease Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, S.-P. Zhao, Y.-C. Cheng, and Y.-L. Li Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease Clin. Chem., August 1, 2003; 49(8): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
